Miscellaneous Malignancies | Norton Healthcare

Indication: Miscellaneous Malignancies

Expanded Access for an Intermediate-size Population for ABI-009 (Sirolimus Albumin-bound Nanoparticles for Injectable Suspension) in Patients with Advanced Metastatic Perivascular Epithelioid Cell Tumors (PEComa) and Patients with a Malignancy with Releva

Advanced Malignancies

Drug Study

Principal Investigator: Don Stevens, M.D.
Norton Cancer Institute

Sponsor: AADI Bioscience, Inc

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.